ישראל - אנגלית - Ministry of Health

pfizer pharmaceuticals israel ltd - crizotinib - capsules - crizotinib 200 mg - crizotinib - crizotinib - xalkori is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive. xalkori is indicated for the treatment of patients with metastatic nsclc whose tumors are ros1-positive.

ישראל - אנגלית - Ministry of Health

pfizer pharmaceuticals israel ltd - crizotinib - capsules - crizotinib 200 mg - crizotinib - crizotinib - xalkori is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive. xalkori is indicated for the treatment of patients with metastatic nsclc whose tumors are ros1-positive.

ישראל - אנגלית - Ministry of Health

pfizer pharmaceuticals israel ltd - crizotinib - capsules - crizotinib 250 mg - crizotinib - crizotinib - xalkori is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive. xalkori is indicated for the treatment of patients with metastatic nsclc whose tumors are ros1-positive.

ישראל - אנגלית - Ministry of Health

pfizer pharmaceuticals israel ltd - crizotinib - capsules - crizotinib 250 mg - crizotinib - crizotinib - xalkori is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive. xalkori is indicated for the treatment of patients with metastatic nsclc whose tumors are ros1-positive.

סינגפור - אנגלית - HSA (Health Sciences Authority)

abbvie pte. ltd. - palivizumab - injection, powder, for solution - 100 mg/vial (100mg/ml) - palivizumab 100 mg/vial (100mg/ml)

סינגפור - אנגלית - HSA (Health Sciences Authority)

pfizer private limited - 84% anhydrous anidulafungin 122mg eqv. anidulafungin - injection, powder, lyophilized, for solution - 100mg/vial - 84% anhydrous anidulafungin 122mg eqv. anidulafungin 100mg/vial

ארמניה - אנגלית - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

hankook korus pharm co. - ibuprofen - tablets film-coated - 400mg

סינגפור - אנגלית - HSA (Health Sciences Authority)

pfizer private limited - medroxyprogesterone acetate - injection - 50 mg/ml - medroxyprogesterone acetate 50 mg/ml

ישראל - אנגלית - Ministry of Health

kamada ltd, israel - alpha-1-antitrypsin ( aat) - solution for infusion - alpha-1-antitrypsin ( aat) 1 g / 50 ml - alfa1 antitrypsin - alpha1-proteinase inhibitor (human), glassia® is indicated for chronic augmentation and maintenance therapy in individuals with congenital deficiency of alpha1-proteinase inhibitor (alpha1-pi), also known as alpha1-antitrypsin (aat) deficiency and clinical evidence of emphysema.

ישראל - אנגלית - Ministry of Health

dexcel ltd, israel - teriparatide - solution for injection - teriparatide 250 mcg/ml - teriparatide - treatment of postmenopausal women with osteoporosis at high risk for fracture: terrosa is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. in postmenopausal women with osteoporosis,terrosa increases bmd reduces the risk of vertebral and nonvertebral fractures . increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture: terrosa is indicated to increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. treatment of men and women with glucocorticoid-induced osteoporosis at high risk for fracture: terrosa is indicated for the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.